Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 365

1.

Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.

Seino Y, Nakamura T, Hirohata M, Kawarabayashi T, Okushima T, Shoji M.

Intern Med. 2018 Nov 19. doi: 10.2169/internalmedicine.1723-18. [Epub ahead of print]

2.

Evaluating the Efficacy and Anti-infective Effect of High-dose Intravenous Immunoglobulin Adjuvant Therapy for Acquired Aplastic Anemia Children.

Bian Z, Zhou N, Qiao X, Lu S, Song X, Zhou H.

J Pediatr Hematol Oncol. 2018 Oct 18. doi: 10.1097/MPH.0000000000001333. [Epub ahead of print]

PMID:
30339655
3.

High-dose intravenous immunoglobulin is strongly associated with hemolytic anemia in patients with Kawasaki disease.

Nolan BE, Wang Y, Pary PP, Luban NLC, Wong ECC, Ronis T.

Transfusion. 2018 Nov;58(11):2564-2571. doi: 10.1111/trf.14879. Epub 2018 Sep 28.

PMID:
30265742
5.

Hepatocellular injury and hematologic cytopenia after high-dose intravenous immunoglobulin administration.

Yuan HL, Yang TC, Zhang W, Wu ZM.

Clin Toxicol (Phila). 2018 Jun 11:1-3. doi: 10.1080/15563650.2018.1483024. [Epub ahead of print] No abstract available.

PMID:
29889569
6.

High-Dose Intravenous Immunoglobulin Treatment of Polyomavirus Nephropathy Developing After T Cell-Mediated Rejection Treatment: A Case Report.

Hwang SD, Lee JH, Lee SW, Kim JK, Kim MJ, Song JH.

Transplant Proc. 2018 Oct;50(8):2575-2578. doi: 10.1016/j.transproceed.2018.01.021. Epub 2018 Jun 2.

PMID:
29871774
7.

High-dose of intravenous immunoglobulin modulates immune tolerance in premature infants.

Liu P, Li L, Fan P, Zheng J, Zhao D.

BMC Pediatr. 2018 Feb 21;18(1):74. doi: 10.1186/s12887-018-1055-5.

8.

A pilot study of high-dose intravenous immunoglobulin 5% for autism: Impact on autism spectrum and markers of neuroinflammation.

Melamed IR, Heffron M, Testori A, Lipe K.

Autism Res. 2018 Mar;11(3):421-433. doi: 10.1002/aur.1906. Epub 2018 Feb 10.

PMID:
29427532
9.

Successful Desensitization of T cell Flow Cytometry Crossmatch Positive Renal Transplant Recipients Using Plasmapheresis and Super High-Dose Intravenous Immunoglobulin.

Kakuta Y, Satoh S, Watarai Y, Aikawa A, Tanabe K, Harada H, Yagisawa T, Ishida H, Okumi M, Takahara S.

Transplant Direct. 2017 Nov 28;4(1):e336. doi: 10.1097/TXD.0000000000000753. eCollection 2018 Jan.

10.

Association of hemolysis with high dose intravenous immunoglobulin therapy in pediatric patients: An open-label prospective trial.

Akman AO, Kara FK, Koksal T, Cakir BC, Karagol C, Sayli T.

Transfus Apher Sci. 2017 Aug;56(4):531-534. doi: 10.1016/j.transci.2017.07.022. Epub 2017 Aug 1.

PMID:
28818402
11.
12.

Bullous Pemphigoid Successfully Treated With a Combination Therapy of Plasmapheresis Followed by Intravenous High Dose Immunoglobulin.

Hattori Y, Takahashi T, Seishima M.

Ther Apher Dial. 2017 Aug;21(4):421-423. doi: 10.1111/1744-9987.12536. Epub 2017 Apr 4. No abstract available.

PMID:
28378368
13.

High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system.

Guarneri A, Cioni M, Rongioletti F.

J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1157-1160. doi: 10.1111/jdv.14244. Epub 2017 Apr 12.

PMID:
28370513
14.

Heart failure not responsive to standard immunosuppressive therapy is successfully treated with high dose intravenous immunoglobulin therapy in a patient with Eosinophilic Granulomatosis with Polyangiitis (EGPA).

Pecoraro A, Crescenzi L, Carucci L, Genovese A, Spadaro G.

Int Immunopharmacol. 2017 Apr;45:13-15. doi: 10.1016/j.intimp.2017.01.025. Epub 2017 Jan 31.

PMID:
28152445
15.

European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology.

Enk A, Hadaschik E, Eming R, Fierlbeck G, French L, Girolomoni G, Hertl M, Jolles S, Karpati S, Steinbrink K, Stingl G, Volc-Platzer B, Zillikens D.

J Dtsch Dermatol Ges. 2017 Feb;15(2):228-241. doi: 10.1111/ddg.13013. Epub 2016 Dec 30.

PMID:
28036140
16.

Tick-borne encephalitis virus neutralization by high dose intravenous immunoglobulin.

Elsterova J, Palus M, Sirmarova J, Kopecky J, Niller HH, Ruzek D.

Ticks Tick Borne Dis. 2017 Feb;8(2):253-258. doi: 10.1016/j.ttbdis.2016.11.007. Epub 2016 Nov 18.

PMID:
27884572
17.

Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study.

Luque Y, Anglicheau D, Rabant M, El Karoui K, Jamme M, Aubert O, Clément R, Noël LH, Bollée G, Brodin-Sartorius A, Martinie M, Kreis H, Timsit MO, Legendre C.

Transpl Int. 2016 Nov;29(11):1205-1215. doi: 10.1111/tri.12833. Epub 2016 Sep 9.

18.

European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology.

Enk AH, Hadaschik EN, Eming R, Fierlbeck G, French LE, Girolomoni G, Hertl M, Jolles S, Karpati S, Steinbrink K, Stingl G, Volc-Platzer B, Zillikens D.

J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1657-1669. doi: 10.1111/jdv.13725. Epub 2016 Jul 13.

19.

Repeated cycles of high-dose intravenous immunoglobulin and plasmapheresis for treatment of late antibody-mediated rejection of renal transplants.

Lee CY, Lin WC, Wu MS, Yang CY, Yeh CC, Tsai MK.

J Formos Med Assoc. 2016 Oct;115(10):845-852. doi: 10.1016/j.jfma.2016.07.007. Epub 2016 Aug 16.

20.

Comparison of high-dose intravenous immunoglobulin (IVIG) in a 5% and a 10% solution does not reveal a significantly different spectrum of side-effects.

Rappold LC, Denk K, Enk AH, Hadaschik EN.

J Eur Acad Dermatol Venereol. 2016 Dec;30(12):e186-e188. doi: 10.1111/jdv.13496. Epub 2015 Nov 9. No abstract available.

PMID:
26551028

Supplemental Content

Loading ...
Support Center